Compare TIMB & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TIMB | RDY |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | Brazil | India |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 9.9B |
| IPO Year | 2020 | 2001 |
| Metric | TIMB | RDY |
|---|---|---|
| Price | $19.48 | $13.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $23.99 | $13.83 |
| AVG Volume (30 Days) | 637.0K | ★ 2.7M |
| Earning Date | 11-03-2026 | 10-23-2026 |
| Dividend Yield | ★ 6.08% | 0.49% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.28 | $4.76 |
| Revenue Next Year | $4.22 | $11.70 |
| P/E Ratio | ★ $15.81 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.14 | $11.36 |
| 52 Week High | $28.22 | $15.67 |
| Indicator | TIMB | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 62.63 | 65.60 |
| Support Level | $17.37 | $12.90 |
| Resistance Level | $20.18 | $13.54 |
| Average True Range (ATR) | 0.54 | 0.21 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 70.58 | 88.60 |
TIM, which is 67%-owned by Telecom Italia, is the third-largest wireless carrier in Brazil, with 62 million subscribers, equal to about 23% of the market. The firm owns 49% of I-Systems, an infrastructure partnership that is expanding its network footprint across Brazil. I-Systems can provide broadband service to about 8 million locations, including 6.5 million with fiber, equal to 10%-15% of the country. TIM leases capacity on the venture's network to serve retail broadband customers under the UltraFibra brand, but it has agreed to buy out its joint venture partner in 2026 and will take full ownership of these assets. TIM also resells fiber network access from other providers.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.